Double-blind, randomised, placebo-controlled, within-subject study (n=20) testing six low/microdoses of oral psilocybin (0, 1, 2, 5, 8, 10 mg) in healthy volunteers to identify doses that improve mood, cognition and sleep without hallucinogenic effects.
This double-blind, randomised, placebo-controlled study administers six separate oral doses of MELOCIN (Psilocybe cubensis powder; 0, 1, 2, 5, 8, 10 mg psilocybin) across six weekly sessions in healthy volunteers to assess safety and potential low-dose effects on mood, cognition and sleep.
Each session involves ingestion of 10 capsules (composition varied to achieve the target dose; placebo day includes 9 placebo + 1 Chaga capsule to mimic after-taste). Sessions are 6–9 days apart with continuous monitoring and blood sampling at multiple acute time points and standardised psychological testing.
Primary objective is safety and tolerability of low/microdoses; secondary outcomes include magnitude of mood, physiological and cognitive effects across doses compared with placebo.
9 placebo capsules + 1 Chaga (Inonotus obliquus) capsule to mimic after-taste
9 placebo + 1 Chaga capsule to mimic mushroom after-taste
Encapsulated Psilocybe cubensis powder delivering 1 mg psilocybin
10 capsules total; composition varied to deliver dose
Encapsulated Psilocybe cubensis powder delivering 2 mg psilocybin
10 capsules total; composition varied to deliver dose
Encapsulated Psilocybe cubensis powder delivering 5 mg psilocybin
10 capsules total; composition varied to deliver dose
Encapsulated Psilocybe cubensis powder delivering 8 mg psilocybin
10 capsules total; composition varied to deliver dose
Encapsulated Psilocybe cubensis powder delivering 10 mg psilocybin
10 capsules total; composition varied to deliver dose